Press Releases

Date Title
Toggle Summary vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update
Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes Initiated two phase 1 clinical studies, mechanistic study of TTP399 and multiple ascending dose study of HPP737 HIGH POINT, N.C. , May 05, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.
View HTML
Toggle Summary vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes
Designation offers potential for expedited development pathway and reinforces TTP399’s potential to provide a substantial clinical benefit HIGH POINT, N.C. , April 13, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the
View HTML
Toggle Summary TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin
HIGH POINT, N.C. , April 12, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that results from the JDRF-supported
View HTML
Toggle Summary vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399
Claims cover methods of reducing HbA1c and the incidence of hypoglycemia using TTP399 in patients with type 1 diabetes HIGH POINT, N.C. , March 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with
View HTML
Toggle Summary vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
HIGH POINT, N.C. , March 18, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced the initiation of a mechanistic study
View HTML
Toggle Summary vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
HIGH POINT, N.C. , March 08, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced its participation in the H.C.
View HTML
Toggle Summary vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Initiation of Mechanistic Study of TTP399 expected during Q1 2021 Announcement of First-Patient First-Visit in Multiple Ascending Dose Phase 1 Study of HPP737 Publication of Phase 2 SimpliciT-1 Results of TTP399 in ADA’s Diabetes Care Journal HIGH POINT, N.C. , Feb.
View HTML
Toggle Summary vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes
Results found a clinically meaningful decrease in frequency of severe and symptomatic hypoglycemia in addition to statistically significant reductions in HbA1c HIGH POINT, N.C. , Feb. 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company
View HTML
Toggle Summary vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
Phase 1 multiple ascending dose study to evaluate safety of HPP737 in healthy volunteers and inform dose selection for phase 2 planned for 2H 2021 Strategic Partner in Asia and Pacific Rim , Newsoara Biopharma, has initiated a phase 2 study in COPD in China HIGH POINT, N.C. , Feb.
View HTML
Toggle Summary vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually
HIGH POINT, N.C. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that it is participating in the LifeSci
View HTML